Nasal hyperreactive disease is a common upper airway disease in clinic. The pathogenesis of the disease with allergic rhinitis (AR) and vasomotor rhinitis (VMR) is complex. At present, the treatment strategy of the disease is mainly to improve the symptoms, but this disease can not be completely cured. Recent studies have found that transient receptor potential (TRP) ion channels may be the important targets for the treatment of nasal hyperreactive disease. Especially with the in-depth researches of transient receptor potential vanilloid 1 (TRPV1), it is found that TRPV1 plays an important role in the neuro-immune regulatory network involved in the occurrence and development of nasal hyperreactive disease. By targeting TRPV1, a variety of drugs have shown promising therapeutic effects and clinical transformation prospect against nasal hyperreactive disease. At present, there is a lack of systematic research on TRPV1 in nasal hyperreactive disease. Therefore, this article reviews the role of TRPV1 in nasal hyperreactive disease, in order to provide theoretical basis and new ideas for the treatment of nasal hyperreactive disease.